ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly U.S. share of consolidated GTN rebate, discount by Year
U.S. share of consolidated GTN rebate, discount & return liability (%) (%)
Eli Lilly U.S. share of consolidated GTN rebate, discount: 87.0% in FY2025, down 3.0 pts from a year earlier.
Latest, FY2025
87.0%
Period ended Dec 31, 2025
Change on a year earlier
-3.0 pts
90.0% in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Where the FY2025 figure comes from
“The portion of our consolidated sales rebate, discount, and return liability balances resulting from sales of our products in the U.S. was approximately 87 percent and 90 percent as of December 31, 2025 and 2024, respectively. The following represents a roll-forward of our most significant U.S. sales rebate, discount, and return liability balances, including managed care, Medicare, Medicaid, chargeback, and patient assistance programs: || || 2025 | 2024 || Sales rebate, discount, and return liabilities, beginning of year | $ | 10,313 | $ | 10,668”
Source: Form 10-K FY2025 (filed 2026-02-12) ↗
Reported in Form 10-K Item 7 Revenue & GTN Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. share of consolidated GTN rebate, discount & return liability (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 87.0% | -3.0 pts | Form 10-K FY2025 (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 90.0% | 0.0 pts | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 90.0% | 0.0 pts | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 90.0% | 0.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 90.0% | 0.0 pts | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 90.0% | 0.0 pts | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 90.0% | 0.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 90.0% | +3.0 pts | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 87.0% | +2.0 pts | Form 10-K FY2017 (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 85.0% | – | Form 10-K FY2017 (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly U.S. share of consolidated GTN rebate, discount (%), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/gtn-us-share-pct
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.